Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 5Cibinetide literatureFrontiers in dental medicine · Review2026

Regenerative peptides for inferior alveolar nerve injury: a narrative review.

Regenerative peptides may offer potential for IAN repair, but current evidence is largely preclinical and lacks direct applicability to human cases. Further research is essential to establish their safety and efficacy.

Read at Frontiers in dental medicineAdd to compare

Where it sits

this study against the rest of the cibinetide corpus
0
Preclinical
2
Observational
0
Open-label
0
Randomised
3
Reviews · this one

Summary and findings

This narrative review assessed the mechanistic rationale and preclinical evidence for regenerative peptides in inferior alveolar nerve injury. It highlighted the potential of ARA-290 (cibinetide) among others, but noted a lack of direct evidence for efficacy in IAN injury. The review emphasizes the need for further research to establish safety and efficacy in relevant models.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2026

Abstract

The authors’ words, as Frontiers in dental medicine supplied them

Inferior alveolar nerve (IAN) injury is a clinically important complication of oral and maxillofacial procedures that can lead to persistent neurosensory impairment, and effective regenerative interventions are presently scarce. This narrative review assessed the mechanistic rationale, preclinical evidence, translational limitations, and potential future relevance of regenerative peptides for IAN repair. Particular attention is given to BPC-157, thymosin <i>β</i>4 (T<i>β</i>4) and its related synthetic fragment TB-500, and ARA-290 (cibinetide), whose reported biological functions intersect with primary mechanisms implicated in peripheral nerve regeneration, such as cellular survival, Schwann cell activity, inflammatory modulation, angiogenesis, extracellular matrix remodeling, and axonal regeneration. Nevertheless, the available evidence is mainly sourced from pre-clinical and non-IAN systems, and direct evidence of efficacy in iatrogenic or traumatic IAN injury remains inadequate. BPC-157 and TB-500 remain investigational compounds with important safety, pharmacokinetic, and regulatory uncertainties, whereas evidence associated with TB-500 should be differentiated from that obtained with full-length T<i>β</i>4. Translation to IAN injury is further complicated by the lack of validated local delivery approaches, uncertain target-site pharmacokinetics, the anatomically restricted mandibular canal, and injury severity. Potential combination strategies involving traditional therapies, biomaterial-assisted delivery frameworks, and dental stem cell-mediated regenerative approaches are mechanistically plausible but remain hypothesis-generating rather than definitive synergistic interventions. Prospective research should prioritize IAN-relevant experimental systems, injury-severity classification, standardized outcome measures, target-site pharmacokinetics, and rigorously controlled clinical trials. Overall, regenerative peptides constitute a biologically plausible but currently investigational method for IAN repair, and their clinical application will rely on exhibiting reproducible efficacy and safety within indication-specific models and human trials.

Background

Inferior alveolar nerve (IAN) injury is a significant complication following oral and maxillofacial procedures, often leading to long-term neurosensory issues. Previous studies have indicated a need for effective regenerative interventions, yet options remain limited. This review aims to explore the potential of regenerative peptides, including Cibinetide, in promoting nerve repair, while addressing the existing gaps in evidence.

Methods

The review synthesizes existing literature on regenerative peptides, focusing on their mechanisms and preclinical findings related to nerve regeneration. It does not present original research data but rather discusses the implications of previously published studies. Specific details on sample size, dose, or duration are not provided.

Results

Not reported in abstract.

Interpretation

The review highlights that while regenerative peptides may have biological plausibility for nerve repair, the evidence primarily stems from non-IAN systems. The lack of robust clinical data and the challenges in translating findings to IAN injury limit the conclusions that can be drawn. The effect sizes and clinical significance of the peptides discussed remain uncertain, necessitating further investigation.

Key findings

  • Not reported in abstract.

Limitations

  • Review based on preclinical evidence.
  • Lacks direct clinical data for IAN injury.
  • Significant uncertainties regarding safety and efficacy.
  • No original research data presented.

Elsewhere in the Cibinetide corpus

CAnti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.Investigative ophthalmology & visual science · 2025 · 30% to 80% decrease in clinical score, P < 0.05.AnimalAInitial estimates of the minimal clinically important difference for the Neuropathic Pain Symptom Inventory: a systematic meta-analysis.Frontiers in pain research (Lausanne, Switzerland) · 2025 · n=12 · MCID for NPSI total score was 6.21 for SD of change meta-regression.reviewDPhase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.Frontiers in neurology · 2025 · Not reported in abstract.reviewCARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.International dental journal · 2025 · 50% reduction in SIRT1 expression within periapical lesions in AP model.Animal